Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No safety/efficacy concerns were behind the reason of trial termination

Conditions

Metastatic Cancer Pancreas

Interventions

DRUG: PF-03084014
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: PF-03084014
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

Pfizer

Collaborators

[object Object]